Peptide of the Week: MOTSC and SS31 - 10% Off This Week
Peptide of the Week: MOTSC and SS31 - 10% Off This Week
Sermorelin is a synthetic 29-amino-acid analogue of growth hormone-releasing hormone, commonly described as GHRH(1-29)NH2 or GRF(1-29) amide. In research settings, sermorelin is studied for its interaction with the growth hormone-releasing hormone receptor, pituitary growth hormone release, pulsatile GH signaling, downstream IGF-1 biology, growth hormone reserve testing and broader somatotropic-axis research. This 2026 guide explains sermorelin’s mechanism, evidence base, pathway context, comparison to related GH-axis peptides and research-use-only quality standards.
Sermorelin is a synthetic GHRH analogue corresponding to the first 29 amino acids of human growth hormone-releasing hormone. It is studied for activation of the GHRH receptor on pituitary somatotroph cells, which can support endogenous growth hormone release and downstream IGF-1 signaling in experimental models. Sermorelin is not the same as exogenous human growth hormone. It is best understood as a GH-axis research peptide focused on pituitary stimulation, GH reserve and GHRH receptor biology.
Sermorelin belongs to the growth hormone-releasing hormone analogue category. It is a truncated, synthetic version of endogenous human GHRH that preserves the biologically active N-terminal 1-29 amino acid sequence. This makes it different from growth hormone itself and different from growth hormone secretagogues that act through ghrelin receptor pathways.
Sermorelin does not replace growth hormone in research models. It is studied as a signal that tells pituitary cells to release growth hormone. That distinction matters because sermorelin acts upstream of GH and IGF-1 rather than serving as GH itself.
For Luxara Labs, sermorelin should be framed as a research-use-only GHRH analogue for laboratory research into the somatotropic axis, pituitary signaling, GH pulse biology, IGF-1 response, age-related endocrine signaling and growth hormone reserve models.
Sermorelin is a synthetic peptide analogue of human growth hormone-releasing hormone. It represents the 1-29 amino acid fragment of endogenous GHRH and is C-terminally amidated, which is why it is often written as GHRH(1-29)NH2.
| Feature | Sermorelin Detail | Research Interpretation |
|---|---|---|
| Common name | Sermorelin | Used as the standard compound name in research and reference databases. |
| Synonyms | GHRH(1-29)NH2, GRF(1-29) amide, sermorelin acetate | These names describe its relationship to growth hormone-releasing hormone. |
| Parent CAS | 86168-78-7 | Common registry number for sermorelin. |
| Acetate CAS | 114466-38-5 | Commonly associated with sermorelin acetate salt. |
| Sequence | Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2 | The active 29-amino-acid GHRH fragment used in receptor-signaling research. |
| Primary receptor | Growth hormone-releasing hormone receptor, GHRHR | Supports research into pituitary somatotroph signaling and GH release. |
| Primary pathway | GHRH, GH and IGF-1 axis | Relevant to somatotropic-axis, endocrine and body-composition pathway research. |
Sermorelin’s mechanism centers on the growth hormone-releasing hormone receptor, which is expressed on pituitary somatotroph cells. Activation of this receptor supports downstream signaling associated with growth hormone release and IGF-1 pathway research.
| Pathway Component | Research Role | Why It Matters for Sermorelin |
|---|---|---|
| GHRH receptor, GHRHR | Primary receptor target for endogenous GHRH and sermorelin-like analogues. | Sermorelin is studied for receptor-mediated pituitary stimulation rather than direct GH replacement. |
| Pituitary somatotroph cells | Cells responsible for growth hormone synthesis and secretion. | Sermorelin research focuses on how GHRH-like signaling influences somatotroph output. |
| Growth hormone, GH | Downstream pituitary hormone released in response to GHRH pathway activation. | GH response is a key experimental readout in sermorelin and GHRH testing models. |
| IGF-1 | Peripheral mediator influenced by GH signaling, especially through hepatic and tissue-level pathways. | IGF-1 is often measured to evaluate downstream GH-axis activity. |
| Somatostatin feedback | Endogenous inhibitory regulator of GH release. | Important because sermorelin-stimulated GH output remains influenced by physiological feedback pathways. |
Sermorelin has been studied in several endocrine and somatotropic-axis contexts. The most relevant research areas include GH reserve testing, pituitary responsiveness, GH pulse modeling, IGF-1 signaling and comparisons with other GH-axis peptides.
| Research Area | What Is Being Studied | Important Limitation |
|---|---|---|
| Growth hormone reserve testing | GH response after stimulation of the GHRH receptor. | Diagnostic and clinical literature should not be converted into instructions for research materials. |
| Pituitary responsiveness | How somatotroph cells respond to GHRH-like receptor activation. | Response depends on biological context, baseline pituitary function and feedback signaling. |
| GH pulse biology | How upstream GHRH signaling affects pulsatile GH release patterns. | Research interpretation differs from direct GH administration models. |
| IGF-1 pathway research | Downstream GH-axis activity through IGF-1-related signaling. | IGF-1 is an indirect downstream marker, not proof of a specific outcome. |
| Age-related endocrine research | How GHRH pathway stimulation has been studied in older adult endocrine and cognitive research settings. | Findings should be interpreted cautiously and not turned into anti-aging claims. |
| GH-axis peptide comparison | How sermorelin differs from CJC-1295, ipamorelin, GHRP-2, GHRP-6 and tesamorelin. | Different receptor targets and half-life profiles make these compounds non-interchangeable. |
Sermorelin is often grouped with other GH-axis peptides, but the compounds differ by receptor target, structure, duration profile and research interpretation.
| Compound | Primary Research Pathway | How It Differs From Sermorelin |
|---|---|---|
| Sermorelin | GHRH receptor activation through GHRH(1-29)NH2 | Short GHRH fragment focused on pituitary GH release and GH reserve models. |
| CJC-1295 no DAC | Modified GHRH analogue | Shares GHRH receptor pathway interest, but differs structurally and in research duration profile. |
| CJC-1295 with DAC | Longer-acting GHRH analogue with albumin-binding design | DAC modification creates a much longer exposure model than sermorelin. |
| Ipamorelin | Ghrelin receptor, GHSR-1a pathway | Acts through the growth hormone secretagogue receptor rather than GHRHR. |
| GHRP-2 | Ghrelin receptor, GHSR-1a pathway | Different receptor class and broader secretagogue profile than sermorelin. |
| GHRP-6 | Ghrelin receptor, GHSR-1a pathway | Different pathway class and historically studied for appetite and GH secretagogue signaling. |
| Tesamorelin | GHRH analogue | Another GHRH analogue, but with different sequence design, evidence base and visceral-adiposity research context. |
Sermorelin, CJC-1295 and tesamorelin belong to the GHRH analogue research category. Ipamorelin, GHRP-2 and GHRP-6 belong to the ghrelin receptor secretagogue research category. They all connect to GH-axis research, but they do not act through the same receptor pathway.
Sermorelin has a deeper historical literature base than many newer peptides because it has been studied as a GHRH analogue, GH reserve tool and pituitary-response compound. Its evidence base should still be interpreted carefully because clinical, diagnostic and research-use contexts are not the same.
| Evidence Area | What the Literature Reports | Research Interpretation |
|---|---|---|
| GHRH analogue identity | Sermorelin is described as GHRH(1-29)NH2, the 29-amino-acid active fragment of human GHRH. | Supports its classification as a GHRH receptor research compound. |
| Diagnostic GH reserve testing | Historical reviews describe sermorelin as a provocative test compound for evaluating growth hormone deficiency. | Relevant to GH reserve models, but not a basis for self-use instructions. |
| Pituitary GH response | Early human studies compared GHRH analogues and evaluated GH response after GHRH stimulation. | Useful for understanding receptor-mediated GH release and pituitary responsiveness. |
| Adult and aging research | Some studies evaluated GHRH(1-29) or sermorelin in older adult endocrine and cognitive research settings. | Findings should not be converted into anti-aging or cognitive-enhancement claims. |
| Combination GH secretagogue research | Published literature includes research on sermorelin combined with GHRP compounds for IGF-1 response models. | Combination literature should not be interpreted as a stacking protocol or use recommendation. |
The GH and IGF-1 axis is biologically complex. Sermorelin research should be interpreted within endocrine feedback systems involving GHRH, somatostatin, ghrelin signaling, pituitary responsiveness, hepatic IGF-1 production and tissue-level GH effects.
The strongest scientific framing is conservative: sermorelin is a GHRH receptor research peptide used to study upstream GH-axis signaling, pituitary responsiveness and downstream IGF-1 biology.
Sermorelin is a peptide research material, so quality evaluation should include identity confirmation, purity, lot-level traceability, storage guidance and research-use-only labeling.
| Standard | Why It Matters |
|---|---|
| Batch-specific COA | Connects the material to lot-level analytical documentation. |
| HPLC purity verification | Supports purity evaluation and impurity visibility. |
| Mass spectrometry identity confirmation | Supports molecular identity confirmation for a 29-amino-acid GHRH analogue. |
| Clear compound naming | Reduces confusion between sermorelin, CJC-1295, tesamorelin and ghrelin receptor secretagogues. |
| Storage and handling guidance | Reduces avoidable degradation, moisture exposure and freeze-thaw variability. |
| Research-use-only labeling | Keeps the material separated from consumer, clinical, hormone therapy, anti-aging or human-use positioning. |
These answers cover the most common sermorelin, GHRH(1-29), GH-axis and IGF-1 pathway research questions in 2026.
Sermorelin is a synthetic analogue of human growth hormone-releasing hormone. It corresponds to GHRH(1-29)NH2, the 29-amino-acid active fragment of GHRH, and is studied for activation of the GHRH receptor on pituitary somatotroph cells.
No. Sermorelin is not growth hormone. It is a GHRH analogue studied for upstream stimulation of pituitary growth hormone release. Growth hormone itself is the downstream hormone released by pituitary somatotroph cells.
Sermorelin targets the growth hormone-releasing hormone receptor, also called GHRHR. This receptor is involved in pituitary GH release and somatotropic-axis signaling research.
The parent CAS number for sermorelin is 86168-78-7. Sermorelin acetate is commonly associated with CAS 114466-38-5. Researchers should confirm whether a supplier is listing the parent compound or acetate salt form.
Sermorelin and CJC-1295 are both connected to GHRH receptor research, but they are not identical. Sermorelin is GHRH(1-29)NH2, while CJC-1295 is a modified GHRH analogue with structural changes that alter its research profile.
Sermorelin acts through the GHRH receptor pathway. Ipamorelin is studied through the ghrelin receptor, also called GHSR-1a. Both connect to GH-axis research, but they work through different receptor systems.
This page does not make anti-aging, performance, body-composition or treatment claims. Sermorelin is discussed strictly as a laboratory research compound used to study GHRH receptor signaling, GH release and downstream IGF-1 biology.
Researchers should look for batch-specific COAs, HPLC purity documentation, mass spectrometry identity confirmation, clear lot numbers, storage guidance and research-use-only labeling.
Luxara Labs ships research-use-only materials across Canada and provides USA-facing research resources and shipping guidance. US-bound shipments may be subject to customs, FDA-related import screening and carrier review.
These references support the sermorelin, GHRH(1-29), growth hormone-releasing hormone receptor, GH reserve, pituitary signaling, IGF-1, GH-axis and research-use context discussed on this page.
Join our list and get an instant 10% discount code — valid for first-time buyers.
